Introduction

Meganor 160 mg (Megestrol Acetate) Tablet is a synthetic progestational agent used for the palliative treatment of advanced breast cancer and endometrial carcinoma, as well as managing anorexia and cachexia in patients with AIDS or cancer. Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified pharmaceutical leader, and supplied globally by Onco Solution, this therapy addresses critical needs in oncology and supportive care. By modulating hormonal pathways and stimulating appetite, Meganor 160 mg (Megestrol Acetate) Tablet improves quality of life in patients with advanced malignancies or debilitating weight loss, offering a dual therapeutic approach.

Key Benefits & Mechanism of Action

Meganor 160 mg (Megestrol Acetate) Tablet combines antineoplastic and appetite-stimulating properties:

1. Anticancer Effects:
   • Inhibits pituitary gonadotropin secretion, reducing estrogen production in hormone-sensitive cancers.
   • Exerts cytotoxic effects on tumor cells and blocks estrogen’s stimulatory action on breast cancer cells.
2. Appetite Stimulation:
   • Promotes weight gain in AIDS/cancer patients by enhancing caloric intake and reducing cachexia.
3. Hormonal Modulation:
   • Competes with estrogen for cytoplasmic receptors, disrupting gene transcription in cancer cells.

Indications

• Advanced Breast/Endometrial Cancer: Palliative treatment for recurrent, inoperable, or metastatic disease.
• AIDS/Cancer-Related Cachexia: Management of significant weight loss, anorexia, or wasting syndrome.

Pharmacology

• Absorption: Peak plasma concentrations reached within 2–3 hours post-dose.
• Half-Life: 33–38 hours, allowing once-daily dosing.
• Excretion: 66% via urine, 20% via feces.
• Protein Binding: High affinity for plasma proteins, prolonging therapeutic effects.

Dosage & Administration

• Breast Cancer: 160 mg once daily.
• Endometrial Carcinoma: 40–320 mg/day in divided doses (minimum 2 months for efficacy assessment).
• Cachexia (Oral Suspension): 800 mg/day (20 mL).
• Administration: Take with food to minimize gastrointestinal discomfort.

Side Effects

Common Reactions:

• Weight Gain: Due to increased appetite (not fluid retention).
• Thromboembolic Events: Thrombophlebitis, pulmonary embolism (monitor high-risk patients).
• Glucocorticoid Effects: Hyperglycemia, Cushing’s syndrome, adrenal insufficiency.

Other Effects:

• Nausea, hypertension, mood changes, rash, sweating, and fatigue.

Contraindications

• Hypersensitivity to megestrol acetate or components.
• Pregnancy (Category D) or suspected pregnancy.

Drug Interactions

• Fluid Retention: Risk increases with concomitant use of estrogens/progestogens.
• Diabetic Patients: May require insulin adjustments due to hyperglycemia.

Warnings & Precautions

• Thromboembolism: Monitor patients with a history of clotting disorders.
• Adrenal Suppression: Taper dose gradually if discontinuing long-term therapy.
• Diabetes: Regular blood glucose monitoring advised.

Use in Special Populations

• Pediatric: Safety not established.
• Geriatric: Limited data; use clinical judgment.
• Lactation: Discontinue breastfeeding due to potential infant risk.

Overdose Management

No life-threatening effects reported at doses up to 1600 mg/day. Manage symptomatically with monitoring.

Storage & Handling

• Store below 30°C in a dry place, protected from light.
• Keep out of children’s reach.

Manufacturer & Supplier

Eskayef Pharmaceuticals Ltd.: A pioneer in affordable oncology therapies, Eskayef’s WHO-GMP-certified facilities ensure global quality standards.
Onco Solution: Delivers Meganor 160 mg (Megestrol Acetate) Tablet to 50+ countries. For orders, visit www.oncosolution.com.

Conclusion

Meganor 160 mg (Megestrol Acetate) Tablet is a versatile therapy for advanced cancer and cachexia, balancing antineoplastic action with appetite stimulation. Trust Eskayef Pharmaceuticals Ltd. for quality and Onco Solution for reliable global access. For clinical or procurement support, contact Onco Solution today.